Informationen:
Fehler:
ID
12808
Beschreibung
A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT01051531
Link
https://clinicaltrials.gov/show/NCT01051531
Stichworte
Versionen (1)
- 21.12.15 21.12.15 -
Hochgeladen am
21. Dezember 2015
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Schizophrenia NCT01051531
Eligibility Schizophrenia NCT01051531
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Schizophrenia NCT01051531
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
informed consent
Item
signed informed consent to participate in the study obtained
boolean
C0021430 (UMLS CUI [1])
informed consent; Pharmacogenomics
Item
signed informed consent to participate in the optional pharmacogenomic component of the study obtained (refusal to give consent for the pharmacogenomic component of the study does not exclude a patient from participation in the clinical study)
boolean
C0021430 (UMLS CUI [1])
C1138555 (UMLS CUI [2])
C1138555 (UMLS CUI [2])
schizophrenia; DSM-IV
Item
confirmation of diagnosis of schizophrenia according to the diagnostic and statistical manual of mental disorders, 4th edition (dsm-iv) within 5 years prior to screening
boolean
C0036341 (UMLS CUI [1])
C0220952 (UMLS CUI [2])
C0220952 (UMLS CUI [2])
compliance
Item
patient is willing and able to fill out self-administered questionnaires during the study
boolean
C1321605 (UMLS CUI [1])
dose Antipsychotic Agents
Item
confirmation that patient has been given an adequate dose of an appropriate oral antipsychotic for an adequate period of time before enrollment, but previous treatment is considered unsuccessful due to one or more of the following reasons: lack of efficacy, lack of tolerability or safety, lack of compliance and/or other reasons to switch to another antipsychotic medication
boolean
C3174092 (UMLS CUI [1,1])
C0040615 (UMLS CUI [1,2])
C0040615 (UMLS CUI [1,2])
diagnosis Psychiatric; Substance Use Disorders
Item
the patient's psychiatric diagnosis is due to the direct pharmacological effects of a drug of abuse substance or medication, or is due to a general medical condition (eg, clinically notable hypothyroidism)
boolean
C0011900 (UMLS CUI [1,1])
C0205487 (UMLS CUI [1,2])
C0038586 (UMLS CUI [2])
C0205487 (UMLS CUI [1,2])
C0038586 (UMLS CUI [2])
Treatment-Resistant
Item
the patient is treatment resistant in the judgment of the investigator
boolean
C4020575 (UMLS CUI [1])
dsm-iv; substance dependence
Item
the patient meets the dsm-iv definition of substance dependence (except for nicotine and caffeine) within 6 months prior to entry
boolean
C0220952 (UMLS CUI [1])
C0038580 (UMLS CUI [2])
C0038580 (UMLS CUI [2])
hypersensitivity risperidone
Item
the patient has a previously defined hypersensitivity (anaphylaxis-type reaction) to risperidone or paliperidone or excipients
boolean
C0020517 (UMLS CUI [1,1])
C0073393 (UMLS CUI [1,2])
C0073393 (UMLS CUI [1,2])
Antipsychotic Agents Injectables; clozapine
Item
the patient has received treatment with a long-acting injectable antipsychotic within 3 injection cycles prior to baseline, received clozapine within 3 months prior to screening, received treatment with other investigational agents within 30 days of the screening visit, has participated in more than one investigational drug study in the past 12 months, or has planned use of other investigational drugs during the time frame of the study
boolean
C0040615 (UMLS CUI [1,1])
C0086466 (UMLS CUI [1,2])
C0009079 (UMLS CUI [2])
C0086466 (UMLS CUI [1,2])
C0009079 (UMLS CUI [2])
comorbidity; cardiovascular disease
Item
history or current symptoms of tardive dyskinesia, history of neuroleptic malignant syndrome, or evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal, neurological, endocrine, metabolic or pulmonary disease in the past 6 months
boolean
C0009488 (UMLS CUI [1])
C0007222 (UMLS CUI [2])
C0007222 (UMLS CUI [2])